newsfilter
← Latest News
GlobeNewswire·

Enliven Therapeutics Announces Details Regarding the Presentation of Updated ELVN-001 Phase 1a Data at the ESH-iCMLf 26th Annual John Goldman Conference on CML

BOULDER, Colo., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Enliven Therapeutics, Inc. (Enliven or the Company) (NASDAQ:ELVN), a clinical-stage precision oncology company focused on the discovery and development of